It's a SMAD/SMAD world

Cullen Taniguchi; Anirban Maitra

doi:10.1016/j.cell.2015.05.030

It's a SMAD/SMAD world

Cullen Taniguchi, Anirban Maitra

Pathology

Research output: Contribution to journal › Short survey › peer-review

6 Scopus citations

Abstract

DPC4/SMAD4 mutations are associated with aggressive pancreatic cancer. In this issue of Cell, Whittle et al. demonstrate that Runx3 expression combined with Dpc4/Smad4 status can predict the metastatic propensity of pancreatic tumors, providing valuable guidance for personalized therapy for patients with pancreatic cancer.

Original language	English (US)
Pages (from-to)	1245-1246
Number of pages	2
Journal	Cell
Volume	161
Issue number	6
DOIs	https://doi.org/10.1016/j.cell.2015.05.030
State	Published - 2015

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.cell.2015.05.030

Cite this

@article{8b98729e731f4dd3bd4166c120c6fc92,

title = "It's a SMAD/SMAD world",

abstract = "DPC4/SMAD4 mutations are associated with aggressive pancreatic cancer. In this issue of Cell, Whittle et al. demonstrate that Runx3 expression combined with Dpc4/Smad4 status can predict the metastatic propensity of pancreatic tumors, providing valuable guidance for personalized therapy for patients with pancreatic cancer.",

author = "Cullen Taniguchi and Anirban Maitra",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier Inc.",

year = "2015",

doi = "10.1016/j.cell.2015.05.030",

language = "English (US)",

volume = "161",

pages = "1245--1246",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - It's a SMAD/SMAD world

AU - Taniguchi, Cullen

AU - Maitra, Anirban

PY - 2015

Y1 - 2015

N2 - DPC4/SMAD4 mutations are associated with aggressive pancreatic cancer. In this issue of Cell, Whittle et al. demonstrate that Runx3 expression combined with Dpc4/Smad4 status can predict the metastatic propensity of pancreatic tumors, providing valuable guidance for personalized therapy for patients with pancreatic cancer.

AB - DPC4/SMAD4 mutations are associated with aggressive pancreatic cancer. In this issue of Cell, Whittle et al. demonstrate that Runx3 expression combined with Dpc4/Smad4 status can predict the metastatic propensity of pancreatic tumors, providing valuable guidance for personalized therapy for patients with pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84934905728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934905728&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2015.05.030

DO - 10.1016/j.cell.2015.05.030

M3 - Short survey

C2 - 26046433

AN - SCOPUS:84934905728

SN - 0092-8674

VL - 161

SP - 1245

EP - 1246

JO - Cell

JF - Cell

IS - 6

ER -

It's a SMAD/SMAD world

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this